#ZikaVirus Stocks Directory Update: Aethlon Medical (Nasdaq: $AEMD) Announces #Zika Virus Data

#ZikaVirus Stocks Directory Update: Aethlon Medical (Nasdaq: $AEMD) Announces #Zika Virus Data

Point Roberts, WA, Delta BC – August 15, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors including biotech and medical technology stocks, issues an updated Zika stocks directory for investors following the sector.

Read this release in full http://www.investorideas.com/news/2016/biotech/08152.asp

Zika Virus Stocks

Aethlon Medical, Inc. (NasdaqCM: AEMD) creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients.  The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients.  Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. 

Aethlon Medical (Nasdaq: AEMD) Announces Zika Virus Data

In vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier

SAN DIEGO – August 11, 2016- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, announced today that its researchers have completed in vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier®. The Hemopurifier® is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies. At present, the immunotherapeutic technology is being advanced through an FDA approved human feasibility study. The Zika studies, which were conducted with small-scale versions of the Hemopurifier®, demonstrated a 95% clearance of Zika virus from cell culture fluid in 5.5 hours and an approximate 50% clearance of Zika from human blood serum in 5 hours.

The studies were conducted with the Zika viral strain that has recently spread from South America to ravage Puerto Rico and likely responsible for the first wave of infections that have begun to occur in the United States. Zika has been declared a global health threat by the World Health Organization and is not addressed with a proven drug or vaccine therapy. According to the CDC, more than 7,300 Americans have been diagnosed with Zika virus infection, including 1,825 individuals in the continental U.S. and Hawaii. Researchers have linked Zika virus infection with Guillain-Barre syndrome, a severe neurological disorder that can cause paralysis. In pregnant women, Zika can cause Microcephaly, which results in babies being born with a small head and underdeveloped brain. Zika infection has also been associated with Arthrogryposis, a condition that results in deformities of joints in the arms and legs of newborns.

“As a result of our research team’s validation of Zika capture, we have further reinforced the potential of our Hemopurifier® to be a first line of defense against the growing list of infectious viral pathogens that are not addressed with traditional drug or vaccine therapies,” stated Aethlon Chairman and CEO, Jim Joyce.

Full news: http://www.investorideas.com/CO/AEMD/news/2016/08111.asp

Cerus Corp. (NasdaqGM: CERS) is a biomedical products company focused in the field of blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood System for plasma and platelets. The INTERCEPT red blood cell system is in clinical development

ZIKA NEWS: http://www.cerus.com/default.aspx?SectionId=5cc5ecae-6c48-4521-a1ad-480e593e4835&LanguageId=1&PressReleaseId=e1e74c5b-6375-4968-837e-e2c010824956

GeneOne Life Science Inc. (KSE:011000.KS; KRX:011000.KR) a biopharmaceutical company, engages in the research and development of DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. Its product pipeline includes VGX-3400, a DNA vaccine, which has completed Phase I clinical trials for the prevention of avian influenza; VGX-3500, a prophylactic pre-pandemic influenza DNA vaccine that is in Phase I clinical trials for protection against swine, avian, and seasonal influenza; and FLUPRIME, a trivalent influenza vaccine, which is in Phase I clinical trials for the prevention of the outbreak of seasonal flu. The company is also developing VGX-6150, a therapeutic DNA vaccine that is in Phase I clinical trials for the treatment of hepatitis C; and therapeutic DNA vaccines for the treatment of hepatitis B. In addition, it is involved in the contract manufacturing activities for various pre-clinical and clinical studies for institutions, universities, governments, and biotechnology companies. GeneOne Life Science Inc. has a collaboration with Inovio Pharmaceuticals, Inc. to test and advance a DNA-based vaccine for preventing and treating the emerging and virulent Zika virus infection. The company was formerly known as VGX International Inc.

GLAXOSMITHKLINE  PLC (NYSE:GSK) creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases

Inovio Pharmaceuticals, Inc (NYSE MKT:INO) is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of cancer immunotherapies and clinical studies, the company is advancing a growing product pipeline. Partners and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba.

http://www.inovio.com/assets/000/000/002/791.pdf

Intrexon Corporation (NYSE:XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. The Company’s integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®.

http://investors.dna.com/Grand-Cayman-will-use-Oxitec-solution-to-suppress-wild-Aedes-aegypti-the-dangerous-mosquito-that-spreads-dengue-Zika-and-chikungunya-in-an-effort-to-help-eliminate-these-diseases

SANOFI-AVENTIS SA (NYSE:SNY; Paris: SAN.PA) a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.

https://lehub.sanofi.com/en/access-healthcare/zika-a-strong-sense-of-urgency/

Full biotech stocks directory: http://www.investorideas.com/BIS/stock_list.asp

About Investorideas.com – News that Inspires Big Ideas

Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: AEMD – August 11, 2016 – one month of PR. News publication and social media – two thousand five hundred

Additional info regarding BC Residents and global Investors: Effective September 15 2008 – all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411